A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Summary
- Eligibility
- for people ages 2 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Ernesto Gonzalez-Giraldo, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Epygenix
- ID
- NCT04462770
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 150 study participants
- Last Updated